Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?

While the PARAGON 58) trial demonstrated a strong trend towards significance for its primary efficacy endpoint, there was a more encouraging signal with regards improvements in quality of life, symptoms and reduced hospitalisations for HFpEF patients.

also in 5,725 other papers